Citius Oncology, Inc. filings document material-event disclosures for an oncology-focused biopharmaceutical company commercializing LYMPHIR™. Recent Form 8-K reports cover operating and financial results following the LYMPHIR launch, international shipment and distribution updates, clinical-study disclosures involving denileukin diftitox-cxdl, and press-release exhibits related to commercial and medical developments.
The filing record also includes emerging growth company disclosures, Nasdaq continued-listing notice reporting, and categories such as material agreements, shareholder voting matters, capital-structure disclosure, governance matters, and security-structure information. These documents frame CTOR’s public reporting around product commercialization, clinical development, corporate governance, listing compliance, and financing-related matters.
Citius Oncology furnished an updated Corporate Presentation under Regulation FD. The company posted the presentation on October 23, 2025 and attached it as Exhibit 99.1 to a Form 8-K. The company states that the information in Item 7.01, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as specifically referenced.
Citius Oncology’s common stock trades on the Nasdaq Capital Market under the symbol CTOR.
Citius Oncology, Inc. (CTOR) is asking shareholders to elect two Class I directors, approve an amendment to its 2024 Omnibus Stock Incentive Plan to increase the share reserve from 15,000,000 to 30,000,000 shares, and to ratify Wolf & Company, P.C. as independent auditor for the fiscal year ending September 30, 2025. The proxy describes voting methods (internet, telephone, mail, or in person), procedures to revoke proxies, and vote thresholds: plurality for director elections and a majority of votes cast for the plan amendment and auditor ratification. The filing discloses director and officer names and ages, option awards and exercise terms (example: options exercisable at $2.15 expiring 07/05/2033), beneficial ownership data based on 83,513,442 shares outstanding as of September 10, 2025, and that certain directors and officers hold options exercisable within 60 days aggregating specific amounts (e.g., Mr. Mazur: 2,466,667 option shares). Compensation tables show selected salary and option grant values for 2023 and 2024 (examples: total reported for one executive was $661,875 in 2023 and $1,275,000 in 2024). The filing also lists committee responsibilities, nomination and shareholder proposal requirements, and corporate governance documents availability on the Company website.
Myron Z. Holubiak, a director and the company secretary of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings. On 09/19/2025 he received 850,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continued service. The filing also reports 100,000 restricted shares granted the same day to his daughter, for which he disclaims beneficial ownership. Previously granted options include 300,000 options (exercise price $1.07) held directly and 50,000 options held indirectly by his daughter, both from a 12/12/2024 grant with 3-year vesting, plus 1,500,000 options (exercise price $2.15) from a 07/05/2023 grant that vest over three years.
Robert Joseph Smith, a director of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings on Form 4. The filing shows a grant of 300,000 restricted shares on 09/19/2025 that vest in three substantially equal annual installments subject to continued service. The report also discloses ownership of 125,000 stock options granted 12/12/2024 with an exercise price of $1.07, exercisable in thirds on each anniversary and expiring 12/12/2034. After the reported restricted-stock grant, the filing lists 300,000 shares beneficially owned directly by the reporting person.
Leonard L. Mazur, Chief Executive Officer and Director of Citius Oncology, Inc. (CTOR), received equity awards on 09/19/2025 that materially change his beneficial ownership. The Form 4 reports a grant of 1,700,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. The filing also shows outstanding stock options: 800,000 options with a $1.07 exercise price and 3,700,000 options with a $2.15 exercise price, each with multi-year vesting schedules. These awards reflect compensation through equity with time-based vesting conditions tied to continued service.
Citius Oncology director Carol Webb received equity compensation disclosed on Form 4. On 09/19/2025 she was granted 300,000 restricted shares that vest in three substantially equal installments on the first, second and third anniversaries of the grant, subject to continuous service. The filing also shows two stock option awards: 125,000 options with a $1.07 exercise price (granted 12/12/2024) and 150,000 options with a $2.15 exercise price (granted 07/05/2023). The 125,000 options vest over three years and the 150,000 options are fully vested. Ownership following the reported transactions is 300,000 shares directly beneficially owned.
Citius Oncology insider equity grants reported by Chief Medical Officer Myron Czuczman. The filing shows restricted stock awards of 825,000 shares granted on 09/19/2025 that vest in three substantially equal annual installments beginning one year after grant, subject to continued service. The reporting person also holds two stock option grants: 400,000 options with a $1.07 exercise price and a 12/12/2034 date shown, and 1,400,000 options with a $2.15 exercise price and a 07/05/2033 date; vesting schedules for the options are described in the filing. All holdings are reported as direct beneficial ownership.
Reporting person: Dennis M. McGrath, Director of Citius Oncology, Inc. (CTOR). Transaction: On 09/19/2025 Mr. McGrath was granted 300,000 restricted common shares at $0, which vest in three substantially equal installments on the first, second and third anniversaries of the grant date, subject to continued service. He also holds two previously reported option grants: a $1.07 exercise-price option for 125,000 shares (granted 12/12/2024; vests one-third each year over three years) and a $2.15 exercise-price option for 150,000 shares (100% vested). Following the 09/19/2025 award, Mr. McGrath beneficially owns 300,000 shares directly plus the options described above. The Form 4 was signed by power of attorney on 09/23/2025.
Jaime Bartushak, Chief Financial Officer of Citius Oncology, Inc. (CTOR), reported equity awards and option holdings on a Form 4. On 09/19/2025 she was granted 825,000 restricted stock awards at no cash price; those shares vest in three substantially equal installments on each of the first three anniversaries of the grant, subject to continued service. The filing also shows two outstanding stock option awards held directly: 400,000 options with a $1.07 exercise price (granted 12/12/2024) and 1,400,000 options with a $2.15 exercise price (vesting began 7/5/2023). The Form was signed by a power of attorney on 09/23/2025.
Citius Oncology director Joel David Mayersohn received 300,000 restricted shares on 09/19/2025, increasing his direct ownership to 321,228 shares. The restricted shares were granted at no cash price and vest in three substantially equal installments on each of the first, second and third anniversaries of the grant date, subject to continued service to the company or a related entity. The filing also reports existing stock options granted 12/12/2024 with an exercise price of $1.07 covering 250,000 underlying shares; those options vest one-third on each of the first, second and third anniversaries of the grant date and are recorded as 250,000 options held directly.